Italia markets open in 8 hours 37 minutes

AxoGen, Inc. (0HKD.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
10,14+1,16 (+12,92%)
Alla chiusura: 03:36PM BST
Schermo intero
Chiusura precedente8,98
Aperto10,15
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno10,14 - 10,15
Intervallo di 52 settimane10,14 - 10,15
Volume280
Media VolumeN/D
Capitalizzazione379,027M
Beta (5 anni mensile)0,74
Rapporto PE (ttm)N/D
EPS (ttm)-0,77
Prossima data utili02 ago 2022 - 08 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference

    ALACHUA, Fla. and TAMPA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president and Peter J. Mariani, executive vice president and CFO will present at two upcoming investor conferences. Mariani will present at the Jefferies Virtual Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET. Zaderej will presen

  • GlobeNewswire

    Axogen, Inc Reports 2022 First Quarter Financial Results

    ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2022. First Quarter 2022 and Business Highlights Net revenue was $31.0 million during the first quarter, matching the first quarter of 2021.Excluding Avive® revenue of $1.7 million in the first quarter of 20

  • GlobeNewswire

    Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft

    RECON achieved its Primary Endpoint, a critical milestone toward transitioning Avance Nerve Graft to a licensed biologic and further supporting the expanded adoption of AvanceALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced topline results from its RECON Clinical Study comparing Avance Nerve Graft to conduits in digital nerve injurie